-transparent.png){kind=logo}
In order to investigate the possible role of bradykinin in the hypotensive mechanism of angiotensin I converting enzyme inhibitor (Captopril) in renin-independent essential hypertension (EHT), we studied the effects of the single administration of 100 mg captopril on plasma bradykinin levels by sensitive radioimmunoassay in 21 EHT, who showed agonistic responses to 1Sar, 8Ile-angiotensin II (A IIA). Fourteen of the patients were low renin and 7 were normal renin EHT. There was no correlation between the baseline plasma renin activity (PRA) and the fall in mean blood pressure (MBP) following captopril administration. When the patients were analyzed according to MBP response, the responders (R) showed a significantly greater bradykinin increment (delta BK, +64%) (p less than 0.05), whereas the nonresponders (NR) did not show such an increase. There was a positive correlation between delta BK and the MBP reduction after captopril in the R group (r = 0.623, p less than 0.05). Plasma aldosterone (PA) decreased profoundly in the R group (-36% from baseline, p less than 0.05). Pretreatment ACE activity was significantly higher in the R group than in the NR group (p less than 0.05). Pressor response to A IIA showed a significantly (p less than 0.05) greater response after captopril administration in the R group. There were no significant differences in blood concentration of captopril between the R and NR groups. The present results suggest that bradykinin may be involved in the hypotensive action of captopril in the EHT subgroup, where the renin-angiotensin system appears to play an inert role for the elevation of blood pressure.
I Miyamori, and
Y Takeda, and
M Ikeda, and
H Koshida, and
S Yasuhara, and
T Morise, and
H Takimoto, and
R Takeda, and
T Nishino
July 1982,
La Clinica terapeutica,
I Miyamori, and
Y Takeda, and
M Ikeda, and
H Koshida, and
S Yasuhara, and
T Morise, and
H Takimoto, and
R Takeda, and
T Nishino
February 1982,
British journal of clinical pharmacology,
I Miyamori, and
Y Takeda, and
M Ikeda, and
H Koshida, and
S Yasuhara, and
T Morise, and
H Takimoto, and
R Takeda, and
T Nishino
May 1981,
British journal of clinical pharmacology,
I Miyamori, and
Y Takeda, and
M Ikeda, and
H Koshida, and
S Yasuhara, and
T Morise, and
H Takimoto, and
R Takeda, and
T Nishino
October 1979,
The Journal of pediatrics,
I Miyamori, and
Y Takeda, and
M Ikeda, and
H Koshida, and
S Yasuhara, and
T Morise, and
H Takimoto, and
R Takeda, and
T Nishino
April 1982,
The Journal of practical nursing,
I Miyamori, and
Y Takeda, and
M Ikeda, and
H Koshida, and
S Yasuhara, and
T Morise, and
H Takimoto, and
R Takeda, and
T Nishino
June 1981,
Archives of internal medicine,
I Miyamori, and
Y Takeda, and
M Ikeda, and
H Koshida, and
S Yasuhara, and
T Morise, and
H Takimoto, and
R Takeda, and
T Nishino
April 1983,
Irish medical journal,
I Miyamori, and
Y Takeda, and
M Ikeda, and
H Koshida, and
S Yasuhara, and
T Morise, and
H Takimoto, and
R Takeda, and
T Nishino
January 1981,
Acta medica Scandinavica. Supplementum,
I Miyamori, and
Y Takeda, and
M Ikeda, and
H Koshida, and
S Yasuhara, and
T Morise, and
H Takimoto, and
R Takeda, and
T Nishino
May 1982,
Israel journal of medical sciences,
I Miyamori, and
Y Takeda, and
M Ikeda, and
H Koshida, and
S Yasuhara, and
T Morise, and
H Takimoto, and
R Takeda, and
T Nishino
October 1980,
The Journal of pediatrics,
